Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141

Thumbnail
View/Open
Date
2022-03-04
ICR Author
Author
Gillison, ML
Blumenschein, G
Fayette, J
Guigay, J
Colevas, AD
Type
Journal Article
Metadata
Show full item record
URI
https://repository.icr.ac.uk/handle/internal/5073
DOI
Collections
Subject
Science & Technology
Life Sciences & Biomedicine
Oncology
clinical trial
squamous cell carcinoma of head and neck
nivolumab
immunotherapy
SQUAMOUS-CELL CARCINOMA
INVESTIGATORS CHOICE
OPEN-LABEL
CETUXIMAB
CHEMOTHERAPY
PLATINUM
Research team
Targeted Therapy
Language
eng
Date accepted
2021-11-30
License start date
2022-03-04
Citation
ONCOLOGIST, 2022, 27 (2), pp. E194 - E198 (5)
Publisher
OXFORD UNIV PRESS
https://creativecommons.org/licenses/by-nc/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/4.0